# Clinical Cancer Research

Source: https://onco.cc/journals/clinical-cancer-research/  
OnCo record `clinical-cancer-research` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AACR's clinical journal: phase 1 dose-escalation trials, biomarker studies, pharmacodynamics and the FDA approval summaries written by agency reviewers.

## Summary

Clinical Cancer Research appears twice a month and is the main venue for phase 1 trials of new oncology drugs, translational biomarker and pharmacokinetic analyses, and the FDA Oncology Center of Excellence approval summaries that explain the evidence behind each new indication. Hybrid access; free after 12 months.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: Clin Cancer Res; CCR; src-clinical-cancer-research
- Publisher: American Association for Cancer Research
- Scope: clinical oncology
- Access: hybrid

## Notes

- Holds: Phase 1 and 2 trials, biomarker studies and CCR Translations commentaries. Access: Paywalled.

## Sources

- AACR Journals: https://aacrjournals.org

## Connected records

- collections: [FDA Oncology Approvals (OCE) & Novel Drug Approvals](https://onco.cc/collections/fda-approvals/)
- institutions: [American Association for Cancer Research (AACR)](https://onco.cc/institutions/aacr/)
- key papers: [A new CA19-9 cutoff value identifies Lewis antigen status and refines prognostic stratification in PDAC](https://onco.cc/key-papers/paper-yeh-ca19-9-lewis-negative-fut3-cutoff-ccr-2026/), [Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE](https://onco.cc/key-papers/paper-alexander-clin-cancer-res/), [Adjuvant temozolomide plus cisplatin versus high-dose interferon versus observation in resected mucosal melanoma](https://onco.cc/key-papers/paper-lian-adjuvant-temozolomide-cisplatin-mucosal-melanoma-ccr-2013/), [Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies](https://onco.cc/key-papers/paper-besser-til-melanoma-intent-to-treat-ccr-2013/), [Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers](https://onco.cc/key-papers/paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013/), [Circulating tumor DNA as a clinical test in resected pancreatic cancer](https://onco.cc/key-papers/paper-groot-kras-ctdna-clinical-test-resected-pancreatic-ccr-2019/), [Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences](https://onco.cc/key-papers/paper-henriksen-ctdna-stage-iii-colorectal-improve-it-ccr-2022/), [Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes](https://onco.cc/key-papers/paper-loree-tumour-location-continuum-colorectal-ccr-2018/), [Combined tumour suppressor defects characterise clinically defined aggressive variant prostate cancers](https://onco.cc/key-papers/paper-aparicio-aggressive-variant-prostate-tumour-suppressors-ccr-2016/), [Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer](https://onco.cc/key-papers/paper-burstein-tnbc-genomic-subtypes-ccr-2015/), [Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention](https://onco.cc/key-papers/paper-giraldo-gallbladder-msk-impact-ccr-2022/), [DART (SWOG 1609): nivolumab plus ipilimumab in rare tumours, non-pancreatic neuroendocrine neoplasms cohort](https://onco.cc/key-papers/paper-dart-nivolumab-ipilimumab-nec-patel-ccr-2020/), [Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis](https://onco.cc/key-papers/paper-berchuck-cfdna-methylation-nepc-detection-ccr-2022/), [Detection of NRG1 gene fusions in solid tumors](https://onco.cc/key-papers/paper-jonna-nrg1-fusions-solid-tumours-ccr-2019/), [DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies](https://onco.cc/key-papers/paper-schultz-clin-cancer-res/), [Differences in prostate cancer genomes by self-reported race](https://onco.cc/key-papers/paper-stopsack-prostate-genomes-by-race-ccr-2022/), [DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1](https://onco.cc/key-papers/paper-ogitani-clin-cancer-res/), [Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer](https://onco.cc/key-papers/paper-arbour-kras-co-mutation-outcomes-ccr-2018/), [Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study](https://onco.cc/key-papers/paper-dll3-sclc-clin-cancer-res-2019/), [FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma](https://onco.cc/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024/), [First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers](https://onco.cc/key-papers/paper-lynch-frameshift-vaccine-ccr-2020/), [GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer](https://onco.cc/key-papers/paper-okane-gata6-basal-like-compass-ccr-2020/), [Genomic analysis of circulating tumour DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms](https://onco.cc/key-papers/paper-tukachinsky-ctdna-3334-advanced-prostate-ccr-2021/), [Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection](https://onco.cc/key-papers/paper-park-hrd-pancreatic-platinum-ccr-2020/), [Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial](https://onco.cc/key-papers/paper-aung-compass-early-results-ccr-2018/), [Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer](https://onco.cc/key-papers/paper-telli-hrd-score-platinum-tnbc-ccr-2016/), [Hu 2018: evaluating mismatch repair deficiency in pancreatic adenocarcinoma, challenges and recommendations](https://onco.cc/key-papers/paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018/), [Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys](https://onco.cc/key-papers/paper-cardillo-clin-cancer-res/), [Jones 2019: NRG1 gene fusions are recurrent, clinically actionable rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma](https://onco.cc/key-papers/paper-jones-nrg1-fusions-recurrent-actionable-kras-wild-type-pdac-ccr-2019/), [Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400](https://onco.cc/key-papers/paper-herbst-clin-cancer-res/), [MAGNOLIA: zanubrutinib in relapsed or refractory marginal zone lymphoma](https://onco.cc/key-papers/paper-magnolia-zanubrutinib-mzl-ccr-2021/), [Mesothelin: a new target for immunotherapy](https://onco.cc/key-papers/paper-mesothelin-mesothelioma-clin-cancer-res-2004/), [Mismatch repair status and BRAF mutation status in metastatic colorectal cancer: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies](https://onco.cc/key-papers/paper-venderbosch-mmr-braf-metastatic-colorectal-pooled-ccr-2014/), [Molecular and clinical determinants of targeted therapy treatment in biliary tract cancer](https://onco.cc/key-papers/paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026/), [Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma](https://onco.cc/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/), [MSH2 loss in primary prostate cancer](https://onco.cc/key-papers/paper-guedes-msh2-loss-primary-prostate-ccr-2017/), [NILE: clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer](https://onco.cc/key-papers/paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019/), [Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)](https://onco.cc/key-papers/paper-ring-clin-cancer-res/), [Oncogenic genomic alterations, clinical phenotypes and outcomes in metastatic castration-sensitive prostate cancer](https://onco.cc/key-papers/paper-stopsack-mcspc-genomic-alterations-outcomes-ccr-2020/), [PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a gamma-secretase inhibitor](https://onco.cc/key-papers/paper-wang-notch-pest-mutations-tnbc-ccr-2015/), [Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177 Lu-Satoreotide Tetraxetan](https://onco.cc/key-papers/paper-reidy-lagunes-clin-cancer-res/), [Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer](https://onco.cc/key-papers/paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013/), [Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker](https://onco.cc/key-papers/paper-pietrasz-ctdna-prognostic-pancreatic-ccr-2017/), [Platinum-based chemotherapy for variant castration-resistant prostate cancer (aggressive variant criteria)](https://onco.cc/key-papers/paper-aparicio-aggressive-variant-ccr-2013/), [Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology](https://onco.cc/key-papers/paper-autio-clin-cancer-res/), [Prostate-specific membrane antigen expression in normal and malignant human tissues](https://onco.cc/key-papers/paper-silver-psma-expression-normal-malignant-tissues-ccr-1997/), [Purity Independent Subtyping of Tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer](https://onco.cc/key-papers/paper-rashid-purist-pancreatic-subtype-classifier-ccr-2020/), [Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma](https://onco.cc/key-papers/paper-pembrolizumab-glioblastoma-clin-cancer-res-2021/), [Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma](https://onco.cc/key-papers/paper-pembrolizumab-glioblastoma-clin-cancer-res-2025/), [Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study](https://onco.cc/key-papers/paper-nct03330847-clin-cancer-res-2026/), [Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma](https://onco.cc/key-papers/paper-idbaih-clin-cancer-res/), [SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies](https://onco.cc/key-papers/paper-cd19-dlbcl-clin-cancer-res-2011/), [Subtype-discordant pancreatic ductal adenocarcinoma tumors show intermediate clinical and molecular characteristics](https://onco.cc/key-papers/paper-topham-subtype-discordant-pancreatic-ccr-2021/), [The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer](https://onco.cc/key-papers/paper-schoenfeld-smarca4-alterations-lung-ccr-2020/), [The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial](https://onco.cc/key-papers/paper-browne-clin-cancer-res/), [Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study](https://onco.cc/key-papers/paper-tracc-clin-cancer-res-2024/), [Triple-negative breast cancer: clinical features and patterns of recurrence](https://onco.cc/key-papers/paper-dent-tnbc-clinical-features-recurrence-ccr-2007/), [Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer](https://onco.cc/key-papers/paper-barroso-sousa-tmb-pten-ici-mtnbc-ccr-2020/), [Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial](https://onco.cc/key-papers/paper-zhou-clin-cancer-res/), [ZEBRA: pembrolizumab in advanced small bowel adenocarcinoma](https://onco.cc/key-papers/paper-zebra-pembrolizumab-small-bowel-adenocarcinoma-ccr-2021/)
- people: [Boris C. Pasche](https://onco.cc/people/boris-pasche/), [Margaret Foti](https://onco.cc/people/margaret-foti/), [Robert A. Winn](https://onco.cc/people/robert-winn/)

---
JSON: https://onco.cc/api/v1/entities/clinical-cancer-research.json